• / Free eNewsletters & Magazine
  • / My Account

EMC

EMC Corp EMC 2 Star

Last Price$29.06Day Change (%)-0.82%
Open Price$29.08Day Change ($)-0.24
Day Range28.68–29.2052-Week Range23.15–29.90

As of Fri 08/01/2014 04:07 PM EST | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. RSA® Web Threat Detection Adds Enhanced Visibility & Analytics; Takes on Mobile Fraud

    RSA® Web Threat Detection Adds Enhanced Visibility & Analytics; Takes on Mobile Fraud

  2. Research and Markets: EMC Filtration (Military, Medical, Automobile, Commercial, Consumer Electronics, & Telecom) Market - Forecast to 2020

    Research and Markets: EMC Filtration (Military, Medical, Automobile, Commercial, Consumer Electronics, & Telecom) Market - Forecast to 2020

  3. Charting the approach of S&P 2,000

    Charting the approach of S&P 2,000

  4. Research and Markets: Global Virtualization Services Market 2014-2018

    Research and Markets: Global Virtualization Services Market 2014-2018

  5. UPDATE: Activist investor plans to push EMC to break up

    UPDATE: Activist investor plans to push EMC to break up

  6. UPDATE: EMC , GoPro jump; BB&T, DaVita, Six Flags sink

    UPDATE: EMC , GoPro jump; BB&T, DaVita, Six Flags sink

  7. RSA's Coviello Calls for Security Industry to Abandon Fear and Trepidation

    RSA's Coviello Calls for Security Industry to Abandon Fear and Trepidation

  8. UPDATE: It's a 'golden age' for activist investors, but not us

    UPDATE: It's a 'golden age' for activist investors, but not us

  9. Research and Markets: Global Enterprise Search Market Forecasts and Opportunities, 2019 - Analysis of the $1.7 Billion Industry

    Research and Markets: Global Enterprise Search Market Forecasts and Opportunities, 2019 - Analysis of the $1.7 Billion Industry

  10. Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic ...

    Phase 2 COSMOS Study Results Published in The Lancet Demonstrate Efficacy and Safety of Janssen’s Once-Daily Simeprevir in All Oral 12-Week Combination with Sofosbuvir for Genotype 1 Chronic Hepatitis C

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.